XYMOGEN Launches Pharmaceutix™ Medical Foods Division and Partners with Acasti Pharma to Bring Revolutionary Medical Food to United States and Beyond

ORLANDO, Fla. – Wednesday, July 11, 2012 – XYMOGEN announced today an exclusive partnership with Acasti Pharma, the biopharmaceutical company with whom they will launch the worldwide distribution of LipiChol540™, a physician-prescribed medical food to manage omega-3 phospholipid deficiency. The formula will be distributed by Pharmaceutix Medical Foods, a wholly owned subsidiary of XYMOGEN.

Acasti, which is headquartered in Canada, was the first to discover the effects of phospholipids, a major component of cell membranes essential for all vital cell processes. The company is a pioneer in the medical use of long-chain omega-3 phospholipids for treatment of chronic cardiovascular and cardiometabolic disorders. Cardiometabolic disorders are associated with a group of risk factors with distinctive metabolic and nutritional requirements. The medical food constitutes an answer, in combination with other medication, to manage primary and secondary dyslipidemic conditions resulting from the cardiometabolic disorder omega-3 phospholipid deficiency.

“We have seen incredible enthusiasm from doctors for LipiChol540™’s ability to lower triglycerides without raising bad low-density lipoprotein (LDL) cholesterol in patients with omega-3 phospholipid deficiency for whom diet and exercise changes are not effective,” said Brian Blackburn, President and CEO of XYMOGEN. “Acasti is a scientific pioneer and our partnership will bring unique and effective products to patients in the United States.”

LipiChol540™ is the only medical krill oil product in the world. It is pharmaceutically formulated to provide a stronger dosage and lower pill burden, compared to popular fish oil supplements, without the typical unpleasant taste or burping side effects.

Medical foods are defined by the FDA as foods specifically formulated to provide nutrients for the management of a disease for which there is a recognized nutrient dysfunction or deficiency component. Medical foods must be used under the care and oversight of a physician, and they must meet the FDA’s rigorous safety requirements.

Krill oil, LipiChol540™’s main ingredient, comes from a small and plentiful ocean fish called krill. Krill oil contains high levels of omega-3 essential fatty acids and antioxidants and has become known as a nutrient-rich “superfood” because it is more easily absorbed into the body than fish oil.

About Acasti Pharma, Inc.

Acasti Pharma is developing a product portfolio of innovative proprietary long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of good high-density lipoprotein (HDL) cholesterol; as such, they play an important role in modulating cholesterol efflux. Acasti Pharma’s phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions in over-the-counter medical food and prescription drug markets.

About XYMOGEN

XYMOGEN, a family-owned, health sciences company headquartered in Orlando, Fla., has been providing high-quality dietary supplements to licensed healthcare practitioners for more than a quarter century. As a nutraceutical company, it has introduced numerous innovations to the functional medicine community. XYMOGEN’s Medical Board of Advisors consists of clinical practitioners who represent a broad range of specialties. The company’s unprecedented growth continues with a new, state-of-the-art 136,000 square foot manufacturing facility and laboratory, as well as a strategic expansion into Canada and Australia, two of the largest international markets. XYMOGEN’s strength as a company was reinforced in 2007, 2008, 2010, and 2011, when it was recognized by Inc. magazine as one of the 5000 fastest-growing private companies in America.

For more information, visit www.xymogen.com.

Please email pr@xymogen.com for comments or inquiries.

# # #

Distributed by Sara Brady Public Relations, Inc.
222 W. Comstock Avenue, Suite 215
Winter Park, Florida 32789
www.sarabradypr.com

For information, contact:
Sara R. Brady
407-702-6632

Tags: